Sparks - Oryzon Genomics

Oryzon Genomics has announced a Notice of Allowance from the United States Patent and Trademark Office for a patent covering iadademstat, and certain other LSD1 inhibitors, in combination with gilteritinib for myeloid cancers including acute myeloid leukaemia (AML). Once granted, the patent is expected to provide US protection until 2042, excluding potential extensions, strengthening the IP position around iadademstat’s Phase Ib FRIDA programme in FLT3-mutated relapsed/refractory AML; a corresponding patent has also been granted in Taiwan, with applications pending elsewhere. The allowance follows encouraging EHA 2026 data from FRIDA, where iadademstat plus gilteritinib delivered a 67% composite complete remission rate at the selected expansion dose in a heavily pre-treated population, alongside a favourable safety profile. Management highlights that this compares favourably with contemporary real-world data for gilteritinib monotherapy in a broadly comparable population, although we note the limitations of cross-study comparisons.

More mature FRIDA and ALICE-2 (in combination with venetoclax and azacitidine in first-line AML) data expected by year-end, representing potentially significant near-term clinical catalysts.